Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

Henry, N. L., Pchejetski, D., A'Hern, R., Nguyen, A. T., Charles, P., Waxman, J., Li, L., Storniolo, A. M., Hayes, D. F., Flockhart, D. A., Stearns, V. and Stebbing, J. (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study. British Journal of Cancer, 103 (3). pp. 291-296. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

Item Type:	Article
Uncontrolled Keywords:	aged,androstadienes,antineoplastic agents,aromatase inhibitors,breast neoplasms,bridged compounds,case-control studies,cytokines,estrogens,female,humans,inflammation,middle aged,musculoskeletal diseases,postmenopause,syndrome,tamoxifen,taxoids
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	Pure Connector
Date Deposited:	16 Dec 2014 10:06
Last Modified:	01 Oct 2024 15:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51536
DOI:	10.1038/sj.bjc.6605768

Actions (login required)

View Item